# Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women

> **NCT02914158** · PHASE3 · UNKNOWN · sponsor: **First Affiliated Hospital, Sun Yat-Sen University** · enrollment: 680 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** Goserelin
- **DRUG:** Tamoxifen
- **DRUG:** Aromatase Inhibitors
- **DRUG:** Leuprolide

## Key facts

- **NCT ID:** NCT02914158
- **Lead sponsor:** First Affiliated Hospital, Sun Yat-Sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-03-30
- **Primary completion:** 2023-12-30
- **Final completion:** 2025-12
- **Target enrollment:** 680 (ESTIMATED)
- **Last updated:** 2023-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02914158

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02914158, "Adjuvant Ovarian Suppression Plus Aromatase Inhibitor or Tamoxifen in Young Women". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT02914158. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*